Document is current
Any future updates will be listed below
-
Authors
Sorgenfrei, Michèle https://orcid.org/0000-0001-8480-197X
Hürlimann, Lea M.
Printz, Andrea https://orcid.org/0000-0002-1487-4767
Wegner, Fanny
Morger, Damien
Ackle, Fabian https://orcid.org/0000-0002-7199-5004
Remy, Mélissa M.
Montowski, Grzegorz https://orcid.org/0009-0002-1589-7239
Keserue, Hans-Anton
Cuénod, Aline https://orcid.org/0000-0002-8522-6134
Imkamp, Frank
Egli, Adrian
Keller, Peter M.
Seeger, Markus A. https://orcid.org/0000-0003-1761-8571
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_170625)
- License Information
-
More Information
Article History
Received: 18 June 2024
Accepted: 4 June 2025
First Online: 14 July 2025
Competing interests
: A patent to protect the nanobody sequences has been applied (UZ513EP). M.S., L.M.H., P.M.K. and M.A.S. are listed as inventors. The flycode technology has been patented (WO2018078167A1). M.A.S. is listed as inventor. L.M.H. is an employee at Linkster Therapeutics AG. M.A.S. is co-founder, shareholder and board member of Linkster Therapeutics AG. D.M. and G.M. are employees of rqmicro AG. H.A.K. is co-founder, shareholder and CEO of rqmicro AG.
